Search hospitals
>
Virginia
>
Charlottesville
University of Virginia Health System
Claim this profile
Charlottesville, Virginia 22901
Global Leader in Lung Cancer
Global Leader in Cancer
Conducts research for Coronary Artery Disease
Conducts research for Ovarian Cancer
Conducts research for Stroke
398 reported clinical trials
52 medical researchers
Summary
University of Virginia Health System is a medical facility located in Charlottesville, Virginia. This center is recognized for care of Lung Cancer, Cancer, Coronary Artery Disease, Ovarian Cancer, Stroke and other specialties. University of Virginia Health System is involved with conducting 398 clinical trials across 567 conditions. There are 52 research doctors associated with this hospital, such as Linda Duska, MD, Scott Lim, MD, Richard D. Hall, and Matthew J. Reilley.
Area of expertise
Lung Cancer
University of Virginia Health System has run 26 trials for Lung Cancer. Some of their research focus areas include:
Cancer
University of Virginia Health System has run 25 trials for Cancer. Some of their research focus areas include:
Top PIs
Linda Duska, MD
University of Virginia Cancer Center
6 years of reported clinical research
Scott Lim, MD
University of Virginia Health System
7 years of reported clinical research
Richard D. Hall
University of Virginia Cancer Center
2 years of reported clinical research
Matthew J. Reilley
University of Virginia Cancer Center
1 year of reported clinical research
Clinical Trials running at University of Virginia Health System
Cancer
Lung Cancer
Stroke
Heart Failure
Prostate Cancer
Ovarian Cancer
Atrial Fibrillation
Small Cell Lung Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Mirvetuximab + Bevacizumab
for Ovarian Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting
2 awards
Phase 3
Pembrolizumab
for Advanced Cancers
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Recruiting
2 awards
Phase 3
4 criteria
LY3537982 + Immunotherapy/Chemotherapy
for Non-Small Cell Lung Cancer
This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
Recruiting
1 award
Phase 3
14 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Virginia Health System?
University of Virginia Health System is a medical facility located in Charlottesville, Virginia. This center is recognized for care of Lung Cancer, Cancer, Coronary Artery Disease, Ovarian Cancer, Stroke and other specialties. University of Virginia Health System is involved with conducting 398 clinical trials across 567 conditions. There are 52 research doctors associated with this hospital, such as Linda Duska, MD, Scott Lim, MD, Richard D. Hall, and Matthew J. Reilley.
Where is University of Virginia Health System located?
The University of Virginia Health System hospital is located at 1215 Lee Street, Charlottesville, VA 22903, on the main campus of the University of Virginia, near the intersection of Lee Street and Jefferson Park Avenue.
Who should I call to ask about financial aid or insurance network?
**University of Virginia Health System Financial Assistance:** - For financial aid, call 866.320.9659 or apply online with the English or Spanish (PDF) forms. - Eligibility is based on a sliding scale of assets, income, and household size, with qualifications including household income within specified ranges and assets under $50,000. **Insurance Inquiries:** - Contact UVA Imaging Billing and Insurance at 866-965-1910 for insurance-related questions. - They accept most major commercial insurance and assist patients with other coverages. Verify coverage with your insurance company before scheduling services. **Graduate Student Health Insurance Subsidy:** - The University mandates health insurance for all students. - Eligible graduate students can receive a Health Insurance Subsidy for the Aetna Student Health plan. - Subsidies may also be available from individual schools or departments for students not meeting initial qualifications.
What insurance does University of Virginia Health System accept?
The University of Virginia Health System accepts a range of insurance plans, including but not limited to the University of Virginia Health Plan, Anthem HealthKeepers Plus (Medicaid), Anthem CCC Plus, Blue Cross and Blue Shield Service Benefit Plan (FEP), Aetna, Cigna, Humana, and Innovation Health. It is important to contact the hospital directly to confirm if your specific insurance plan is accepted, as coverage may vary for different services and providers. Understanding your insurance policy and potential financial responsibilities, including separate bills from physicians and ancillary services, is also crucial.
What awards or recognition has University of Virginia Health System received?
The University of Virginia Health System in Charlottesville, Virginia, stands out for its exceptional research and care, earning the title of Best Hospital in Virginia in Newsweek's "World’s Best Hospitals 2022" and a Top Teaching Hospital by the Leapfrog Group. It has also received the highest rating for care in 5 specialties and 14 common conditions and procedures according to U.S. News & World Report. Furthermore, the University of Virginia School of Medicine has recognized its researchers with prestigious awards like the Distinguished Research Award and the Research Mentor Award for their groundbreaking contributions to medicine.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.